Mykotische Keratitis: Klinische Zeichen, Diagnose, Therapie

Mathias Roth; Friedrich Steindor; Oliver Kurzai; Wolfgang Behrens-Baumann; Colin R. Mackenzie; Gerd Geerling

doi:10.1055/a-0646-6404

Augenheilkunde up2date, Table of Contents

Augenheilkunde up2date 2020; 10(01): 8-16
DOI: 10.1055/a-0646-6404

Handlungspfade

Georg Thieme Verlag KG Stuttgart · New York

Mykotische Keratitis: Klinische Zeichen, Diagnose, Therapie

Mathias Roth‡

,

Friedrich Steindor‡

,

Oliver Kurzai

,

Wolfgang Behrens-Baumann

,

Colin R. Mackenzie

,

Gerd Geerling

Abstract

All articles of this category

Ein erhabenes Infiltrat, Satellitenherde und ein pyramidenförmiges Hypopyon sind nahezu pathognomonisch für eine mykotische Keratitis. Dieser typische Befund ist in solcher Eindeutigkeit jedoch selten, meist wird die korrekte Diagnose spät gestellt. Insbesondere bei fortgeschrittenen Befunden kann es zu einem Verlust des Auges kommen. Aus diesem Grund empfehlen wir eine zügige und aggressive Therapie, die entsprechend des Verlaufs aktiv angepasst wird.

Full Text

References

Literatur
1 Gower EW, Keay LJ, Oechsler RA. et al. Trends in fungal keratitis in the United States, 2001 to 2007. Ophthalmology 2010; 117: 2263-2267
2 Tuli SS, Iyer SA, Driebe WT. Fungal keratitis and contact lenses: An old enemy unrecognized or a new nemesis on the block?. Eye Contact Lens 2007; 33: 415-417
3 Roth M, Daas L, Renner-Wilde A. et al. Das Deutsche Pilz-Keratitis-Register. Ophthalmologe 2019; 116: 957-966 doi:10.1007/s00347-019-0871-9
4 Dahlgren MA, Lingappan A, Wilhelmus KR. The clinical diagnosis of microbial keratitis. Am J Ophthalmol 2007; 143: 940-944
5 Tuft SJ, Tullo AB. Fungal keratitis in the United Kingdom 2003–2005. Eye (Lond) 2009; 23: 1308-1313
6 Nielsen SE, Nielsen E, Julian HO. et al. Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013. Acta Ophthalmol 2015; 93: 54-58
7 Behrens-Baumann W. Zur klinischen Diagnose der Pilzkeratitis. Z prakt Augenheilkd 2010; 31: 577-580
8 Behrens-Baumann W, Finis D, MacKenzie C. et al. Keratomykose – Therapiestandards und aktuelle Entwicklungen. Klin Monatsbl Augenheilkd 2015; 232: 754-764
9 Roth M, Schrader S, Finis D. et al. Diagnostik von Binde- und Hornhauterkrankungen: Teil 2: Diagnostik infektiöser Hornhaut- und Bindehauterkrankungen. Klin Monatsbl Augenheilkd 2015; 232: 789-806
10 Kheirkhah A, Syed ZA, Satitpitakul V. et al. Sensitivity and Specificity of Laser-Scanning In Vivo Confocal Microscopy for Filamentous Fungal Keratitis: Role of Observer Experience. Am J Ophthalmol 2017; 179: 81-89
11 Das S, Sharma S, Kar S. et al. Is inclusion of Sabouraud dextrose agar essential for the laboratory diagnosis of fungal keratitis?. Indian J Ophthalmol 2010; 58: 281-286
12 Thomas PA, Teresa PA, Theodore J. et al. PCR for the molecular diagnosis of mycotic keratitis. Expert Rev Mol Diagn 2012; 12: 703-718
13 Bharathi MJ, Ramakrishnan R, Meenakshi R. et al. Microbiological diagnosis of infective keratitis: comparative evaluation of direct microscopy and culture results. Br J Ophthalmol 2006; 90: 1271-1276
14 Al-Badriyeh D, Leung L, Roydhouse T. et al. Prospective open-label study of the administration of two-percent voriconazole eye drops. Antimicrob Agents Chemother 2009; 53: 3153-3155
15 Martin MJ, Rahman MR, Johnson GJ et al. Mycotic keratitis: Susceptibility to antiseptic agents. Int Ophthalmol 1995; 19: 299-302
16 Rahman MR, Johnson GJ, Husain R. et al. Randomised trial of 0.2 % chlorhexidine gluconate and 2.5 % natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol 1998; 82: 919-925
17 Prajna NV, Krishnan T, Mascarenhas J. et al. The mycotic ulcer treatment trial. JAMA Ophthalmol 2013; 131: 422-429
18 Sharma S, Das S, Virdi A. et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol 2015; 99: 1190-1195
19 Guidelines for the Management of corneal Ulcer at primary, secondary & tertiary Care Health Facilities in the South-East Asia Region. New Delhi: World Health Organization Regional Office for South-East; 2004
20 Sharma N, Sahay P, Maharana PK. et al. Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol. Cornea 2019; 38: 141-145
21 Bourcier T, Sauer A, Dory A. et al. [Fungal keratitis]. J Fr Ophtalmol 2017; 40: 882-888
22 FlorCruz NV, Peczon I, Evans JR. Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2015; (02) CD004241
23 Sradhanjali S, Yein B, Sharma S. et al. In vitro synergy of natamycin and voriconazole against clinical isolates of Fusarium, Candida, Aspergillus and Curvularia spp. Br J Ophthalmol 2018; 102: 142-145
24 Sharma N, Chacko J, Velpandian T. et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Ophthalmology 2013; 120: 677-681
25 Prajna NV, Mascarenhas J, Krishnan T. et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol 2010; 128: 672-678
26 Prajna NV, Krishnan T, Rajaraman R. et al. Effect of oral voriconazole on fungal keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II) a randomized clinical trial. JAMA Ophthalmol 2016; 134: 1365-1372
27 Titiyal JS, Velpandian T, Maharana PK. et al. Comparison of Oral Voriconazole Versus Oral Ketoconazole as an Adjunct to Topical Natamycin in Severe Fungal Keratitis. Cornea 2017; 36: 1521-1527
28 Niki M, Eguchi H, Hayashi Y. et al. Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis. Clin Ophthalmol 2014; 8: 1075
29 Prakash G, Sharma N, Goel M. et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008; 146: 56-59
30 Kalaiselvi G, Narayana S, Krishnan T. et al. Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol 2015; 99: 195-198
31 Sharma N, Agarwal P, Sinha R. et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: Case series. Br J Ophthalmol 2011; 95: 1735-1737
32 Narayana S, Krishnan T, Ramakrishnan S. et al. Mycotic Antimicrobial Localized Injection (MALIN): A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole. Ophthalmology 2019; 126: 1084-1089 doi:10.1016/j.ophtha.2019.03.020
33 Tu EY, Majmudar PA. Adjuvant stromal amphotericin B injection for late-onset DMEK infection. Cornea 2017; 36: 1556-1558
34 Garcia-Valenzuela E, Song CD. Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis. Arch Ophthalmol 2005; 123: 1721-1723
35 Sahay P, Singhal D, Nagpal R. et al. Pharmacologic therapy of mycotic keratitis. Surv Ophthalmol 2019; 64: 380-400 doi:10.1016/j.survophthal.2019.02.007
36 Bell RW, Ritchey JP. Subconjunctival nodules after amphotericin B injection. Medical therapy for Aspergillus corneal ulcer. Arch Ophthalmol 1973; 90: 402-404
37 Kaji Y, Yamamoto E, Hiraoka T. et al. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B. Graefeʼs Arch Clin Exp Ophthalmol 2009; 247: 549-553
38 Carrasco MA, Genesoni G. Treatment of severe fungal keratitis with subconjunctival amphotericin B. Cornea 2011; 30: 608-611
39 Pate JC, Jones DB, Wilhelmus KR. Prevalence and spectrum of bacterial co-infection during fungal keratitis. Br J Ophthalmol 2006; 90: 289-292
40 Matoba AY, Divatia MK, Arguello RA. et al. Clinically Significant Enhancement of Voriconazole Efficacy by Moxifloxacin and Gentamicin in Fungal Keratitis. Cornea 2018; 37: 651-654
41 Green K, Bowman K, Hull DS. Chlorhexidine Effects on Epithelium and Endothelium. Arch Ophthalmol 1980; 98: 1273-1278
42 Panda A, Ahuja R, Biswas NR. et al. Role of 0.02% polyhexamethylene biguanide and 1% povidone iodine in experimental Aspergillus keratitis. Cornea 2003; 22: 138-141
43 Behrens-Baumann W, Seibold M, Hofmüller W. et al. Benefit of polyhexamethylene biguanide in Fusarium keratitis. Ophthalmic Res 2012; 48: 171-176
44 Fiscella RG, Moshifar M, Messick CR. et al. Polyhexamethylene biguanide (PHMB) in the treatment of experimental Fusarium keratomycosis. Cornea 1997; 16: 447-449
45 Rebong RA, Santaella RM, Goldhagen BE. et al. Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. Investig Ophthalmol Vis Sci 2011; 52: 7309-7315
46 Raghavan A, Baidwal S, Venkatapathy N. et al. The Acanthamoeba-Fungal keratitis study. Am J Ophthalmol 2019; 201: 31-36 doi:10.1016/j.ajo.2019.01.024
47 Rosetta P, Legrottaglie EF, Pagano L. et al. Corneal Cross-Linking Window Absorption (CXL-WA) as an Adjuvant Therapy in the Management of Aspergillus niger Keratitis. Case Rep Ophthalmol Med 2018; 2018: 4856019 doi:10.1155/2018/4856019
48 Erdem E, Harbiyeli II, Boral H. et al. Corneal Collagen Cross-Linking for the Management of Mycotic Keratitis. Mycopathologia 2018; 183: 521-527
49 Li Z, Jhanji V, Tao X. et al. Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol 2013; 97: 669-671
50 Chen Y, Yang W, Gao M. et al. Experimental study on cryotherapy for fungal corneal ulcer. BMC Ophthalmol 2015; 15: 29 doi:10.1186/s12886-015-0011-5
51 Duncan JK, Chen Y, Belin MW. et al. Excisional keratectomy combined with focal cryotherapy and amniotic membrane inlay for recalcitrant filamentary fungal keratitis: A retrospective comparative clinical data analysis. Exp Ther Med 2016; 12: 3014-3020
52 Kim HJ, Lim HR, Koh JW. Cryotherapy on Refractory Fungal Corneal Ulcer: A Case Report. J Korean Ophthalmol Soc 2017; 58: 1194
53 Fili S, Schilde T, Perdikakis G. et al. Two Cases of Keratomycosis Caused by Fusarium Solani: Therapeutic Management. J Eye Cataract Surg 2016;
54 Kocluk Y, Cubuk M, Sukgen E. et al. Early Therapeutic Penetrating Keratoplasty for Fungal Keratitis. J Immunol Clin Microbiol 2016; 1: 18 doi:10.5455/jicm.3.20160510
55 Xie L, Dong X, Shi W. Treatment of fungal keratitis by penetrating keratoplasty. Br J Ophthalmol 2001; 85: 1070-1074
56 Li C, Zhao GQ, Che CY. et al. Effect of corneal graft diameter on therapeutic penetrating keratoplasty for fungal keratitis. Int J Ophthalmol 2012; 5: 698-703 doi:10.3980/j.issn.2222-3959.2012.06.09
57 Perry HD, Doshi SJ, Donnenfeld ED. et al. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 2002; 21: 161-163
58 Pandit RT. Antifungal effects of cyclosporine A. Cornea 2003; 22: 92-93
59 Zhong J, Peng L, Wang B. et al. Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis. Mol Vis 2018; 24: 187-200